Jennifer M. Bratt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jennifer M. Bratt has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Jerold A. Last
5 shared publicationsLisa M. Franzi
Center for Comparative Respiratory Biochemistry and Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, School of Medicine, University of California-Davis, 451 Health Sciences Drive, Davis, CA 95616, USA
4 shared publicationsNicholas J. Kenyon
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, CA 95817
4 shared publications- Nicholas J. Kenyon
Department of Internal Medicine, 4150 V Street, Suite 3400, University of California, Davis, Sacramento, CA 95817, USA
4 shared publications Angela L. Linderholm
Department of Pulmonary and Critical Care Medicine, CCRBM, School of Medicine, University of California, Davis, CA 95616, USA
3 shared publicationsMichael S. Last
Pulmonary and Critical Care Medicine, School of Medicine, Genome and Biomedical Sciences Facility, Suite 6500, 451 Health Sciences Dr., University of California, Davis, CA 95616, USA
3 shared publications
Latest Publications
- 1 June 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 200 (11) , 3840-3856
Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation
Ras, a small GTPase protein, is thought to mediate Th2-dependent eosinophilic inflammation in asthma. Ras requires cell membrane association for its biological activity, and this requires the posttranslational modification of Ras with an isoprenyl group by farnesyltransferase (FTase) or geranylgeranyltransferase (GGTase). We hypothesized that inhibition of FTase using FTase inhibitor (FTI)–277 would attenuate allergic asthma by depleting membrane-associated Ras. We used the OVA mouse model of allergic inflammation and human airway epithelial (HBE1) cells to determine the role of FTase in inflammatory cell recruitment. BALB/c mice were first sensitized then exposed to 1% OVA aerosol or filtered air, and half were injected daily with FTI-277 (20 mg/kg per day). Treatment of mice with FTI-277 had no significant effect on lung membrane–anchored Ras, Ras protein levels, or Ras GTPase activity. In OVA-exposed mice, FTI-277 treatment increased eosinophilic inflammation, goblet cell hyperplasia, and airway hyperreactivity. Human bronchial epithelial (HBE1) cells were pretreated with 5, 10, or 20 μM FTI-277 prior to and during 12 h IL-13 (20 ng/ml) stimulation. In HBE1 cells, FTase inhibition with FTI-277 had no significant effect on IL-13–induced STAT6 phosphorylation, eotaxin-3 peptide secretion, or Ras translocation. However, addition of exogenous FPP unexpectedly augmented IL-13–induced STAT6 phosphorylation and eotaxin-3 secretion from HBE1 cells without affecting Ras translocation. Pharmacological inhibition of FTase exacerbates allergic asthma, suggesting a protective role for FTase or possibly Ras farnesylation. FPP synergistically augments epithelial eotaxin-3 secretion, indicating a novel Ras-independent farnesylation mechanism or direct FPP effect that promotes epithelial eotaxin-3 production in allergic asthma.
- 1 June 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 200 (11) , 3840-3856
Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation
Ras, a small GTPase protein, is thought to mediate Th2-dependent eosinophilic inflammation in asthma. Ras requires cell membrane association for its biological activity, and this requires the posttranslational modification of Ras with an isoprenyl group by farnesyltransferase (FTase) or geranylgeranyltransferase (GGTase). We hypothesized that inhibition of FTase using FTase inhibitor (FTI)–277 would attenuate allergic asthma by depleting membrane-associated Ras. We used the OVA mouse model of allergic inflammation and human airway epithelial (HBE1) cells to determine the role of FTase in inflammatory cell recruitment. BALB/c mice were first sensitized then exposed to 1% OVA aerosol or filtered air, and half were injected daily with FTI-277 (20 mg/kg per day). Treatment of mice with FTI-277 had no significant effect on lung membrane–anchored Ras, Ras protein levels, or Ras GTPase activity. In OVA-exposed mice, FTI-277 treatment increased eosinophilic inflammation, goblet cell hyperplasia, and airway hyperreactivity. Human bronchial epithelial (HBE1) cells were pretreated with 5, 10, or 20 μM FTI-277 prior to and during 12 h IL-13 (20 ng/ml) stimulation. In HBE1 cells, FTase inhibition with FTI-277 had no significant effect on IL-13–induced STAT6 phosphorylation, eotaxin-3 peptide secretion, or Ras translocation. However, addition of exogenous FPP unexpectedly augmented IL-13–induced STAT6 phosphorylation and eotaxin-3 secretion from HBE1 cells without affecting Ras translocation. Pharmacological inhibition of FTase exacerbates allergic asthma, suggesting a protective role for FTase or possibly Ras farnesylation. FPP synergistically augments epithelial eotaxin-3 secretion, indicating a novel Ras-independent farnesylation mechanism or direct FPP effect that promotes epithelial eotaxin-3 production in allergic asthma.
- 1 December 2011
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 257 (2) , 182-188
Why is particulate matter produced by wildfires toxic to lung macrophages?
- 1 December 2011
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 257 (2) , 182-188
Why is particulate matter produced by wildfires toxic to lung macrophages?
- Open Access
- 1 September 2011
- Published by Elsevier in Journal of Biomedical Research
- Vol. 25 (5) , 299-308
Competitive metabolism of L -arginine: arginase as a therapeutic target in asthma
- 1 September 2011
- Published by Elsevier in Journal of Biomedical Research
- Vol. 25 (5) , 299-308
Open AccessCompetitive metabolism of L -arginine: arginase as a therapeutic target in asthma
- Open Access
- 12 January 2011
- Published by MDPI AG in Pharmaceuticals
- Vol. 4 (1) , 187-201
L-Arginine Supplementation and Metabolism in Asthma
L-Arginine, the amino acid substrate for nitric oxide synthase, has been tested as a therapeutic intervention in a variety of chronic diseases and is commonly used as a nutritional supplement. In this study, we hypothesized that a subset of moderate to severe persistent asthma patients would benefit from supplementation with L-arginine by transiently increasing nitric oxide levels, resulting in bronchodilation and a reduction in inflammation. The pilot study consisted of a 3 month randomized, double-blind, placebo-controlled trial of L-arginine (0.05 g/kg twice daily) in patients with moderate to severe asthma. We measured spirometry, exhaled breath nitric oxide, serum arginine metabolites, questionnaire scores, daily medication use and PEFR with the primary endpoint being the number of minor exacerbations at three months. Interim analysis of the 20 subjects showed no difference in the number of exacerbations, exhaled nitric oxide levels or lung function between groups, though participants in the L-arginine group had higher serum L-arginine at day 60 (2.0 ± 0.6 × 10−3 vs. 1.1 ± 0.2 × 10−3 µmol/L, p < 0.05), ornithine at day 30 (2.4 ± 0.9 vs. 1.2 ± 0.3 µmol/L serum, p < 0.05) and ADMA at day 30 (6.0 ± 1.5 × 10−1 vs. 2.6 ± 0.6 × 10−1 µmol/L serum, p < 0.05) on average compared to the placebo group. The study was terminated prematurely. Supplementing asthma subjects with L-arginine increases plasma levels; whether subgroups might benefit from such supplementation requires further study.
- 12 January 2011
- Published by MDPI AG in Pharmaceuticals
- Vol. 4 (1) , 187-201
Open AccessL-Arginine Supplementation and Metabolism in Asthma
L-Arginine, the amino acid substrate for nitric oxide synthase, has been tested as a therapeutic intervention in a variety of chronic diseases and is commonly used as a nutritional supplement. In this study, we hypothesized that a subset of moderate to severe persistent asthma patients would benefit from supplementation with L-arginine by transiently increasing nitric oxide levels, resulting in bronchodilation and a reduction in inflammation. The pilot study consisted of a 3 month randomized, double-blind, placebo-controlled trial of L-arginine (0.05 g/kg twice daily) in patients with moderate to severe asthma. We measured spirometry, exhaled breath nitric oxide, serum arginine metabolites, questionnaire scores, daily medication use and PEFR with the primary endpoint being the number of minor exacerbations at three months. Interim analysis of the 20 subjects showed no difference in the number of exacerbations, exhaled nitric oxide levels or lung function between groups, though participants in the L-arginine group had higher serum L-arginine at day 60 (2.0 ± 0.6 × 10−3 vs. 1.1 ± 0.2 × 10−3 µmol/L, p < 0.05), ornithine at day 30 (2.4 ± 0.9 vs. 1.2 ± 0.3 µmol/L serum, p < 0.05) and ADMA at day 30 (6.0 ± 1.5 × 10−1 vs. 2.6 ± 0.6 × 10−1 µmol/L serum, p < 0.05) on average compared to the placebo group. The study was terminated prematurely. Supplementing asthma subjects with L-arginine increases plasma levels; whether subgroups might benefit from such supplementation requires further study.
- 1 December 2010
- Published by Elsevier in Translational Research
- Vol. 156 (6) , 335-349
Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling?
- 1 December 2010
- Published by Elsevier in Translational Research
- Vol. 156 (6) , 335-349
Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling?
- Open Access
- 5 October 2010
- Published by Wiley in Mediators of Inflammation
- Vol. 2010, 1-15
Nitric Oxide Synthase Enzymes in the Airways of Mice Exposed to Ovalbumin: NOS2 Expression Is NOS3 Dependent
Objectives and Design. The function of the airway nitric oxide synthase (NOS) isoforms and the lung cell types responsible for its production are not fully understood. We hypothesized that NO homeostasis in the airway is important to control inflammation, which requires upregulation, of NOS2 protein expression by an NOS3-dependent mechanism.Materials or Subjects. Mice from a C57BL/6 wild-type,,, andgenotypes were used. All mice strains were systemically sensitized and exposed to filtered air or ovalbumin (OVA) aerosol for two weeks to create a subchronic model of allergen-induced airway inflammation.Methods. We measured lung function, lung lavage inflammatory and airway epithelial goblet cell count, exhaled NO, nitrate and nitrite concentration, and airway NOS1, NOS2, and NOS3 protein content.Results. Deletion of NOS1 or NOS3 increases NOS2 protein present in the airway epithelium and smooth muscle of air-exposed animals. Exposure to allergen significantly reduced the expression of NOS2 protein in the airway epithelium and smooth muscle of thestrain only. This reduction in NOS2 expression was not due to the replacement of epithelial cells with goblet cells as remaining epithelial cells did not express NOS2.animals had significantly reduced goblet cell metaplasia compared to C57Bl/6 wt,, andallergen-exposed mice.Conclusion. The airway epithelial and smooth muscle cells maintain a stable airway NO concentration under noninflammatory conditions. This “homeostatic” mechanism is unable to distinguish between NOS derived from the different constitutive NOS isoforms. NOS3 is essential for the expression of NOS2 under inflammatory conditions, while NOS1 expression contributes to allergen-induced goblet cell metaplasia.- 5 October 2010
- Published by Wiley in Mediators of Inflammation
- Vol. 2010, 1-15
Open AccessNitric Oxide Synthase Enzymes in the Airways of Mice Exposed to Ovalbumin: NOS2 Expression Is NOS3 Dependent
Objectives and Design. The function of the airway nitric oxide synthase (NOS) isoforms and the lung cell types responsible for its production are not fully understood. We hypothesized that NO homeostasis in the airway is important to control inflammation, which requires upregulation, of NOS2 protein expression by an NOS3-dependent mechanism.Materials or Subjects. Mice from a C57BL/6 wild-type,,, andgenotypes were used. All mice strains were systemically sensitized and exposed to filtered air or ovalbumin (OVA) aerosol for two weeks to create a subchronic model of allergen-induced airway inflammation.Methods. We measured lung function, lung lavage inflammatory and airway epithelial goblet cell count, exhaled NO, nitrate and nitrite concentration, and airway NOS1, NOS2, and NOS3 protein content.Results. Deletion of NOS1 or NOS3 increases NOS2 protein present in the airway epithelium and smooth muscle of air-exposed animals. Exposure to allergen significantly reduced the expression of NOS2 protein in the airway epithelium and smooth muscle of thestrain only. This reduction in NOS2 expression was not due to the replacement of epithelial cells with goblet cells as remaining epithelial cells did not express NOS2.animals had significantly reduced goblet cell metaplasia compared to C57Bl/6 wt,, andallergen-exposed mice.Conclusion. The airway epithelial and smooth muscle cells maintain a stable airway NO concentration under noninflammatory conditions. This “homeostatic” mechanism is unable to distinguish between NOS derived from the different constitutive NOS isoforms. NOS3 is essential for the expression of NOS2 under inflammatory conditions, while NOS1 expression contributes to allergen-induced goblet cell metaplasia. - 1 January 2010
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 242 (1) , 1-8
Arginase inhibition in airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin
- 1 January 2010
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 242 (1) , 1-8
Arginase inhibition in airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin
- 5 November 2008
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 234 (3) , 273-280
Arginase enzymes in isolated airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin
- 5 November 2008
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 234 (3) , 273-280
Arginase enzymes in isolated airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin
- 1 August 2008
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 230 (3) , 269-275
Arginases I and II in lungs of ovalbumin-sensitized mice exposed to ovalbumin: Sources and consequences
- 1 August 2008
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 230 (3) , 269-275
Arginases I and II in lungs of ovalbumin-sensitized mice exposed to ovalbumin: Sources and consequences
- 15 September 2006
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 20 (6) , 660-668
Influence of pirfenidone on airway hyperresponsiveness and inflammation in a Brown-Norway rat model of asthma
- 15 September 2006
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 20 (6) , 660-668
Influence of pirfenidone on airway hyperresponsiveness and inflammation in a Brown-Norway rat model of asthma